ENSG Stock Analysis: The Ensign | NASDAQ

Nursing Care, Senior Living, Rehabilitative Services, Post-Acute Leasing

Total Rating 51

Safety 74

Buy Signal -0.31

Medical Care Facilities
Industry Rotation: +4.3

Market Cap: 9.86B
Avg Turnover: 63.5M

Risk 3d forecast

Volatility23.6%

VaR 5^th Pctl3.91%

VaR vs Median0.43%

Reward TTM

Sharpe Ratio-0.10

Rel. Str. IBD32.4

Rel. Str. Peer Group32.5

Character TTM

Beta0.167

Beta Downside0.305

Hurst Exponent0.519

Drawdowns 3y

Max DD31.81%

CAGR/Max DD0.69

CAGR/Mean DD2.84

EPS (Earnings per Share)

EPS CAGR: 16.70%
EPS Trend: 99.3%

Last SUE: 1.67
Qual. Beats: 1

Revenue

Rev. CAGR: 16.89%
Rev. Trend: 99.8%

Last SUE: -0.09
Qual. Beats: 0

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

Confidence

Seasonality 11.7 years of data

Jan -1.6% 21

Feb +0.8% 7

Mar -0.9% 8

Apr -1.5% 31

May +1.2% 5

Jun -0.2% 7

Jul +1.5% 18

Aug +1.9% 10

Sep -6.8% 37

Oct +1.6% 21

Nov +2.0% 12

Dec -1.4% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ENSG The Ensign

The Ensign Group (ENSG) is a U.S. healthcare company that operates skilled nursing facilities, senior living communities, and rehabilitative services across 16 states, with a footprint concentrated in the West, South, and Midwest.

The company operates through two segments. The Skilled Services segment provides short- and long-term nursing care for patients with chronic conditions or prolonged illness, along with specialty offerings such as on-site dialysis, ventilator care, and cardiac and pulmonary management. The Standard Bearer segment functions as a real estate operation, leasing post-acute care properties to third-party healthcare operators-an unusual structure within the Health Care Facilities sub-industry that separates property ownership from facility operations.

In addition, ENSG runs senior living units and provides ancillary services including digital x-ray, ultrasound, electrocardiograms, sub-acute care, respiratory services, long-term care pharmacy, patient transportation, and mobile diagnostics. Skilled nursing operators in this segment typically rely on Medicare and Medicaid reimbursement, making them sensitive to changes in federal and state payment policies. The company was incorporated in 1999 and is headquartered in San Juan Capistrano, California.

Headlines to Watch Out For

Skilled nursing occupancy and rate growth boost revenue
Medicare and Medicaid reimbursement changes impact revenue
Acquisition pipeline expansion fuels facility count growth

Piotroski VR-10 (Strict) 6.5

Net Income: 378.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.68 > 1.0
NWC/Revenue: 3.40% < 20% (prev 6.75%; Δ -3.35% < -1%)
CFO/TA 0.11 > 3% & CFO 608.4m > Net Income 378.7m
Net Debt (4.04b) to EBITDA (621.3m): 6.50 < 3
Current Ratio: 1.21 > 1.5 & < 3
Outstanding Shares: last quarter (59.5m) vs 12m ago 1.50% < -2%
Gross Margin: 14.14% > 18% (prev 15.88%; Δ -1.74% > 0.5%)
Asset Turnover: 102.8% > 50% (prev 93.60%; Δ 9.15% > 0%)
Interest Coverage Ratio: 65.04 > 6 (EBIT TTM 506.7m / Interest Expense TTM 7.79m)

Altman Z'' 2.73

A: 0.03 (Total Current Assets 1.07b - Total Current Liabilities 884.8m) / Total Assets 5.75b
B: 0.34 (Retained Earnings 1.95b / Total Assets 5.75b)
C: 0.09 (EBIT TTM 506.7m / Avg Total Assets 5.34b)
D: 0.74 (Book Value of Equity 2.44b / Total Liabilities 3.30b)
Altman-Z'' = 2.73 = A

Beneish M -2.84

DSRI: 0.97 (Receivables 668.9m/578.0m, Revenue 5.49b/4.61b)
GMI: 1.12 (GM 15.88% / 14.14%)
AQI: 0.94 (AQ_t 0.08 / AQ_t-1 0.08)
SGI: 1.19 (Revenue 5.49b / 4.61b)
TATA: -0.04 (NI 378.7m - CFO 608.4m) / TA 5.75b)
Beneish M = -2.84 (Cap -4..+1) = A

What is the price of ENSG shares?

As of October 10, 2026, the stock is trading at USD 171.80 with a total of 205,323 shares traded. Over the past week, the price has changed by +0.01%, over one month by +0.06%, over three months by +1.74% and over the past year by -2.20%.

Current recommended Stop Loss: 166.10 (which is 3.3% or 1.5 ATR below the current price).

Is ENSG a buy, sell or hold?

The Ensign has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy ENSG.

StrongBuy: 3
Buy: 1
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ENSG price?

Analysts Target Price	220	28.1%

The Ensign (ENSG) - Fundamental Data Overview as of 09 October 2026

Market Cap USD = 9.86b (9.86b USD * 1.0 USD.USD)
P/E Trailing = 26.5235
P/E Forward = 20.7039
P/S = 1.7975
P/B = 4.1753
P/EG = 1.3792
Revenue TTM = 5.49b USD
EBIT TTM = 506.7m USD
EBITDA TTM = 621.3m USD
Long Term Debt = 135.6m USD (from longTermDebt, last quarter)
Short Term Debt = 125.3m USD (from shortTermDebt, last quarter)
Debt = 4.36b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.11b
Net Debt = 4.04b USD (calculated: Debt 4.36b - CCE 320.8m)
Enterprise Value = 13.9b USD (9.86b + Debt 4.36b - CCE 320.8m)
Interest Coverage Ratio = 65.04 (Ebit TTM 506.7m / Interest Expense TTM 7.79m)
EV/FCF = 33.17x (Enterprise Value 13.9b / FCF TTM 419.1m)
FCF Yield = 3.01% (FCF TTM 419.1m / Enterprise Value 13.9b)
FCF Margin = 7.64% (FCF TTM 419.1m / Revenue TTM 5.49b)
Net Margin = 6.90% (Net Income TTM 378.7m / Revenue TTM 5.49b)
Gross Margin = 14.14% ((Revenue TTM 5.49b - Cost of Revenue TTM 4.71b) / Revenue TTM)
Gross Margin QoQ = 16.65% (prev 16.40%)
Tobins Q-Ratio = 2.42 (Enterprise Value 13.9b / Total Assets 5.75b)
Interest Expense / Debt = 0.18% (Interest Expense 7.79m / Debt 4.36b)
Taxrate = 24.03% (119.9m / 498.9m)
NOPAT = 385.0m (EBIT 506.7m * (1 - 24.03%))
Current Ratio = 1.21 (Total Current Assets 1.07b / Total Current Liabilities 884.8m)
Debt / Equity = 1.79 (Debt 4.36b / totalStockholderEquity, last quarter 2.44b)
Debt / EBITDA = 6.50 (Net Debt 4.04b / EBITDA 621.3m)
Debt / FCF = 9.64 (Net Debt 4.04b / FCF TTM 419.1m)
Total Stockholder Equity = 2.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 378.7m / Total Assets 5.75b)
RoE = 16.53% (Net Income TTM 378.7m / Total Stockholder Equity 2.29b)
RoCE = 20.89% (EBIT 506.7m / Capital Employed (Equity 2.29b + L.T.Debt 135.6m))
RoIC = 8.16% (NOPAT 385.0m / Invested Capital 4.72b)
WACC = 4.60% (E(9.86b)/V(14.2b) * Re(6.57%) + D(4.36b)/V(14.2b) * Rd(0.18%) * (1-Tc(0.24)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.02 | Cagr: 1.19%
[DCF] Terminal Value 77.97% ; FCFF base≈362.2m ; Y1≈415.2m ; Y5≈611.0m
[DCF] Fair Price = 88.44 (EV 9.19b - Net Debt 4.04b = Equity 5.15b / Shares 58.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.35 | EPS CAGR: 16.70% | SUE: 1.67 | # QB: 1
Revenue Correlation: 99.82 | Revenue CAGR: 16.89% | SUE: -0.09 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.96 | Chg30d=+0.00% | Revisions=+62% | Analysts=5
EPS current Year (2026-12-31): EPS=7.79 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+18.6% | GrowthRev=+16.8%
EPS next Year (2027-12-31): EPS=8.56 | Chg30d=+0.07% | Revisions=+62% | GrowthEPS=+9.8% | GrowthRev=+10.7%
[Analyst] Revisions Ratio: +83% (up=15, down=0)